Business
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
DURHAM, N.C., March 26, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2024, and provided a business update.
About this update from Precision Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/78f083adecd21d1a55ef972bce1a1b2f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ddd.vuyiQskGsyhP0kl9fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/78f083adecd21d1a55ef972bce1a1b2f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4s7nnnQCCk_FkXrrVzZGyQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/78f083adecd21d1a55ef972bce1a1b2f","width":1024,"height":512}},"lazy":false},{"type":"text","content":"- Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 -","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"- Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth quarter of 2024 -","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"- Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis B surface antigen after only one administration at lowest dose level; Subsequent doses of PBGENE-HBV to follow with data expected throughout 2025 -","length":271,"tagName":"p","attribs":{}},{"type":"text","content":"- Announced complete clinical response in first infant dosed by partner iECURE in ongoing Phase 1/2 clinical trial in Ornithine Transcarbamylase (OTC) Deficiency -","length":163,"tagName":"p","attribs":{}},{"type":"text","content":"- Anticipated cash runway into the second half of 2026 is expected to enable achievement of key Phase 1 clinical inflection points across both wholly owned in vivo gene editing programs -","length":187,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C., March 26, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2024, ...